SAMSUNG BIOLOGICS

World Rank (Jul-30-2023)
418
Market Cap (Jul-30-2023)
43.80 Billion USD
World Rank (Dec-25-2022)
354
Market Cap (Dec-25-2022)
44.81 Billion USD
World Rank (Jan-07-2022)
417
Market Cap (Jan-07-2022)
46.573 Billion USD
World Rank (Jan-01-2021)
318
Market Cap (Jan-01-2021)
50.610 Billion USD
Annual Revenue in USD
2,356 Million USD
Annual Net Income in USD
626 Million USD
Total Assets in USD
13,017 Million USD
Total Liabilities in USD
5,964 Million USD
Annual Results for Year ending in
Dec-2022 month
Headquarters Country
South Korea
Headquarters Sub Region
Eastern Asia
Headquarters Continent
Asia
Company Business
Healthcare
Pharmaceutical
Biopharmaceutical
Biotechnology
HealthCare Products
Stock Exchange
South Korea
Company Rank in Country in 2022
Company Rank in South Korea in 2022 is 3
Rank in Country (Jan-2021)
Company Rank in South Korea in 2021 is 4
Rank in Country (Jan-2020)
Rank in South Korea in 2020 is 4
Number of Employees
2,587
Employee Count as on Date
As on 2022
CEO:
John Rim
Yahoo @ SouthKorea
Wikipedia
Company Website:
Samsung Biolgics
About Company Business:

Samsung Biologics is Biopharmaceutical Manufacturing Company with headquarters in South Korea. It provides development, manufacturing , laboratory testing services at every stage for Biopharmaceutical products while meeting the evolving needs of the global healthcare industry. The company has 2,587 employees as on 2022.

Founded Year
2011
Annual Results Summary:

SAMSUNG BIOLOGICS - Yearly Results - Revenue and Net Profit - in Billion KRW:

Annual Ending Revenue Operating Profit Net Profit
Dec-2021 1,568 537 393
Dec-2020 1,164 292 240
Dec-2019 701 91 202
Dec-2018 535 55 224
Balance Sheet Summary

Total Assets as on Dec-2021 is 7,970 Billion KRW.

Total Liabilities as on Dec-2021 is 2,978 Billion KRW.

Total Equity as on Dec-2021 is 4,991 Billion KRW.

Share it on Social Media